Nationale Nederlanden Polskie Towarzystwo Emerytalne S.A., the largest institutional investor in Central and Eastern Europe, has announced holding 8.86% of the shares of multiQure – a GPW-listed company developing an innovative gene therapy for Huntington’s disease. The fund joined the Company’s shareholder base by participating in the series S share issue completed on 22 June this year as part of an accelerated bookbuild offering (ABB). This is the second – after Esaliens TFI – major institutional investor to disclose a stake among multiQure’s shareholders.
The idea behind multiQure is to implement the American biotechnology model in Poland, which involves concentrating resources and capital on a leading project and proving the therapy’s efficacy in real clinical conditions as quickly as possible. The flagship asset in multiQure’s portfolio is an RNAi platform targeting the treatment of Huntington’s disease and other polyglutamine diseases.
– The disclosure of another major fund among our shareholders confirms for us the soundness of the goals we have set for multiQure’s RNAi therapy. NN PTE is the largest institutional investor in the CEE region, particularly active in the global biotechnology market. The inclusion of our company in its investment portfolio positions us among the leading players in this sector – comments Sławomir Wójcik, member of the Management Board of multiQure.
Nationale Nederlanden PTE is among the funds and family foundations that acquired shares of the Company as part of the series S share issue carried out on 22 June this year under the ABB formula. Esaliens TFI, one of the leading independent Polish investment fund management companies, had previously disclosed a stake in the Company’s shareholder base. Through the transaction, the Company raised PLN 50 million, which will be allocated to a number of milestones, including the production of the viral vector, the administration of the therapy to the first patients, and obtaining preliminary results confirming the therapy’s efficacy and safety profile. In parallel, the Company will prepare a clinical trial application (IND submission) to the FDA or another regulator.